 | Description & Citation--Study No. 3404 | | | ICPSR Study No.: | 3404 |
|---|
| | | Title: | Drug Abuse Treatment Outcome Study--Adolescent (DATOS-A), 1993-1995: [United States] |
|---|
| | | Alternate Title: | DATOS-A |
|---|
| | | Principal Investigator(s): | United States Department of Health and Human
Services. National Institute on Drug Abuse |
|---|
| | | Funding Agency: | United States Department of Health and Human
Services. National Institute on Drug Abuse (NIDA) |
|---|
| | | Grant Number: | U01-DA10377, N01DA-9-8233 |
|---|
| | | Bibliographic Citation: | U.S. Dept. of Health and Human Services, National
Institute on Drug Abuse. DRUG ABUSE TREATMENT OUTCOME
STUDY--ADOLESCENT (DATOS-A), 1993-1995: [UNITED STATES] [Computer
file]. Conducted by the Coordinating DATOS Research Center at the
National Development and Research Institutes (NDRI), North Carolina,
and collaborating research centers at Texas Christian University and
the University of California at Los Angeles, with data collected by
the Research Triangle Institute. ICPSR03404-v3. Ann Arbor, MI:
Inter-university Consortium for Political and Social Research
[producer and distributor], 2007-02-19. |
|---|
| | | | Summary: | Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A)
was a multisite, prospective, community-based, longitudinal study of
adolescents entering treatment. It was designed to evaluate the
effectiveness of adolescent drug treatment by investigating the
characteristics of the adolescent population, the structure and
process of drug abuse treatment in adolescent programs, and the
relationship of these factors with outcomes. Adolescent patients
admitted to one of three types of substance abuse treatment programs
across six cities were interviewed during 1993-1995. The three major
types or modalities of programs included in the study were chemical
dependency or short-term inpatient (STI), therapeutic community or
residential (RES), and outpatient drug-free (ODF). The adolescent
battery of instruments included intake, in-treatment, and follow-up
questionnaires based largely on the DATOS adult study Drug Abuse
Treatment Outcome Study (DATOS), 1991-1994: [United States] (ICPSR
2258) instrument format, with considerable tailoring to the adolescent
population.
Clients entering treatment completed two comprehensive intake
interviews (Intake 1 and Intake 2), approximately one week apart. This
information is provided in Parts 1 and 2 of the data collection. These
interviews were designed to obtain baseline data on drug use and other
behaviors, such as illegal involvement, as well as information on
background and demographic characteristics, education and training,
mental health status, employment, income and expenditures, drug and
alcohol dependence, health, religiosity and self-concept, and
motivation and readiness for treatment. The one-, three-, and
six-month in-treatment interviews (Parts 3, 4, and 7) included items
on treatment access, in-treatment experience, and psychological
functioning, as well as questions replicated from some of the domains
in the Intake 1 and 2 questionnaires. The 12-Month Post-Treatment
Follow-Up Interview (Part 5) included questions replicated from the
previous interviews, and also included post-treatment status. Part 6
includes variables for time in treatment and interview availability
indicators. The Measures Data (Part 8) were generated by using the
Diagnostic and Statistical Manual of Mental Disorders (Rev. 3rd ed.,
DSM-III-R) (American Psychiatric Association, 1987). The variables in
Part 8 give either the DSM-III-R level of dependence to a drug
category or they describe whether the subject meets the DSM-III-R
standard for a particular disorder. The 12-Month Follow-Up Urine
Result data (Part 9) provide the results from urine sample tests that
were given to a sample of subjects at the time of the 12-Month
Follow-Up Interview. The urine test was used to ascertain the nature
and extent of bias in the self-reports of the respondents. Urine
specimens were tested for eight categories of drugs (amphetamines,
barbiturates, benzodiazepines, cannabinoids, cocaine metabolite,
methaqualone, opiates, and phencyclidine). The drugs covered in the
study were alcohol, tobacco, marijuana (hashish, THC), cocaine
(including crack), heroin, narcotics or opiates such as morphine,
codeine, Demerol, Dilaudid, and Talwin, illegal methadone, sedatives
and tranquilizers such as barbiturates and depressants, amphetamines
or other stimulants such as speed or diet pills, methamphetamines,
LSD, PCP, and other hallucinogens or psychedelics, and inhalants such
as glue, gasoline, paint thinner, and aerosol sprays. The study also
included drug of choice, frequency, and route of administration. |
|---|
| | | Subject Term(s): | adolescents, alcohol abuse, drug abuse, drug treatment, mental health, substance abuse treatment, treatment outcome, treatment programs |
|---|
| | | Geographic Coverage: | United States |
|---|
| | | Time Period: | 1993 - 1995 |
|---|
| | | Date(s) of Collection: | 1993 - 1995 |
|---|
| | | Unit of Observation: | individual |
|---|
| | | Universe: | Clients admitted to selected drug treatment programs in
the United States in 1993-1995. |
|---|
| | | Data Type: | survey data, and clinical data |
|---|
| | | Data Collection Notes: | (1) Users are advised that the data are most
appropriately analyzed by modality. (2) The Intake 1 and Intake 2 data
files contain several continuous variables that denote age at the time
of a certain event. For some of these variables, dichotomous codes 1
and 95 were also used for "don't know but under 15" and "don't know
but 15 or older," respectively. Code 1 was also used for actual
responses of "1 year old." Because it is unlikely that these events
occurred at age 1, the code 1 was changed to 94 ("1 or don't know but
under 15") in order to make it clearer that this code denotes
something other than age 1. Users are cautioned that this may have an
effect on any analyses performed using these variables. (3) Users are
advised that some DATOS-A publications exclude data from two sites
that had low response rates. However, the public use files include
data from all six sites. (4) DATOS-A is an ongoing collaborative
research effort of the National Development and Research Institutes at
North Carolina (NDRI), Texas Christian University, the University of
California at Los Angeles, and NIDA. For additional information, see
the DATOS Web site. (link) |
|---|
| | | | Sample: | Six cities located in different sections of the United
States were selected for the study because they each had a sufficient
number of adolescent programs to support the research design. All six
cities were medium to large metropolitan areas with established
treatment systems. These cities were a subset of the sites for the
DATOS adult study DRUG ABUSE TREATMENT OUTCOME STUDY (DATOS),
1991-1994: [UNITED STATES] (ICPSR 2258). Treatment programs were
purposefully sampled and included (1) programs that treated an
adolescent population separately from an adult population and (2)
programs with projected patient admissions of at least five patients
per month. Thirty-seven programs participated in the study.
Respondents were sampled from among those admitted to treatment in
1993-1995. A total of 3,382 clients participated in the Intake
interview. Of those, 2,258 participated in the one-month intreatment
interview, 1,120 participated in the three-month intreatment
interview, and 1,785 participated in the 12-month follow-up. The
intake treatment sample was 74 percent male, 24 percent African
American, and 21 percent Hispanic, with a mean age of between 15 and
16 years and a mean of 9 years education. Over half had some juvenile
or criminal justice status at admission, two-thirds had no prior drug
treatment experience, and the predominant drug-use patterns included
weekly or daily use of marijuana alone or combined with alcohol. For
the urine testing that was done at the 12 month follow-up, 25 percent
of the respondents interviewed at follow-up were randomly selected to
provide a urine sample for testing. A total of 464 respondents were
asked to provide a specimen. Urine specimens suitable for testing were
obtained for 417, and results were available for 362 respondents and
analyzed at a NIDA-certified laboratory. |
|---|
| | | Mode of Data Collection: | face-to-face interview |
|---|
| | | Response Rates: | 2,974 of the clients who completed the intake
interview were selected as eligible for the 12-month follow-up
interview (reasons for ineligibility include incarceration,
hospitalization, language barrier, and living outside of the
metropolitan interviewing area). Of these eligible clients, 65.9
percent (n = 1,960) were located, 60 percent (n = 1,785) were
successfully interviewed, .5 percent (n = 14) were deceased, and 5.4
percent (n = 161) refused to participate. |
|---|
| | | | Note: | A list of the data formats available for this study can be found in the
summary of holdings. Detailed file-level information (such as LRECL, case count, and variable count) is listed in the
file manifest. |
|---|
| | | Restrictions: | Users are reminded by the National Institute on Drug
Abuse (NIDA) that these data are to be used solely for statistical
analysis and reporting of aggregated information and not for the
investigation of specific individuals or organizations. |
|---|
| | | Original ICPSR Release: | 2004-02-05 |
|---|
| | | Version History: | The last update of this study occurred on 2007-02-19. |
|---|
| | |
| 2007-02-19 - SAS transport (XPORT), SPSS portable,
and Stata system files were added to Parts 1-5. Some corrections
were made to the codebooks. |
|---|
| | |
| 2005-11-04 - On 2005-03-14 new files were added to
one or more datasets. These files included additional setup files as
well as one or more of the following: SAS program, SAS transport, SPSS
portable, and Stata system files. The metadata record was revised
2005-11-04 to reflect these additions. |
|---|
| | |
| 2004-06-23 - Three datasets were added to the study:
6-Month Intreatment Data (Part 7), Measures Data (Part 8, and 12-Month
Follow-Up Urine Result Data (Part 9). Corresponding documentation was
prepared for each. Value labels were added for one variable (MUSA) in
Part 5, 12-Month Follow-Up Data. |
|---|
| | | Dataset(s): | - DS1: Intake 1 Data
- DS2: Intake 2 Data
- DS3: 1-Month Intreatment Data
- DS4: 3-Month Intreatment Data
- DS5: 12-Month Follow-Up Data
- DS6: Time in Treatment and Interview Availability Indicators
- DS7: 6-Month Intreatment Data
- DS8: Measures Data
- DS9: 12-Month Follow-Up Urine Result Data
|
|---|
| |
|  |
